Oxybutynin

What oxybutynin (as oxybutynin chloride/hydrochloride) is and how it works

Oxybutynin is a medicine that relaxes the muscle of the bladder wall, used to treat overactive bladder symptoms -- a sudden, strong urge to urinate (urgency), needing to urinate more often than usual (frequency), and leaking urine before reaching the toilet (urge incontinence). (1)

Oxybutynin does not carry a boxed warning, but it does have a genuine, serious warning: rarely, it can cause angioedema (sudden swelling of the face, lips, tongue, or throat), which can occur even after the very first dose and can be life-threatening if it affects breathing. It also commonly causes dry mouth, constipation, and blurred vision because of how it works on the body's muscarinic receptors, and it can affect thinking and heat tolerance, especially in older adults.

Mechanism of action: how oxybutynin (as oxybutynin chloride/hydrochloride) works

Oxybutynin is a competitive antagonist at muscarinic acetylcholine receptors (particularly M3) on bladder smooth muscle, and also has a direct antispasmodic action on detrusor smooth muscle. This combined anticholinergic and antispasmodic effect reduces involuntary bladder contractions, increasing bladder capacity and reducing urgency, frequency, and urge incontinence. (1) (2)

What oxybutynin (as oxybutynin chloride/hydrochloride) is used for

Before taking oxybutynin (as oxybutynin chloride/hydrochloride)

Do not take / not appropriate for

• Do not take oxybutynin if you have urinary retention (difficulty emptying your bladder) or a bladder outflow blockage. (all countries) (1) (2)
• Do not take oxybutynin if you have gastric retention, a bowel blockage, paralytic ileus, toxic megacolon, or another severe condition that slows down your gut. (all countries) (1) (2) (6)
• Do not take oxybutynin if you have uncontrolled narrow-angle glaucoma, or (per the UK and New Zealand sources reviewed) any condition with a narrow anterior chamber angle. (all countries) (1) (2) (6)
• Do not take oxybutynin if you have myasthenia gravis, or severe ulcerative colitis -- confirmed as contraindications in the UK and New Zealand sources reviewed. (United Kingdom, New Zealand) (2) (6)
• Do not take oxybutynin if you have a known serious allergic reaction to oxybutynin or its ingredients. (all countries) (1)

Tell your clinician about

• Any history of glaucoma or eye problems.
• Any history of bowel or bladder problems, including difficulty emptying your bladder.
• Any history of Parkinson's disease, autonomic neuropathy, or hiatus hernia with reflux.
• Any memory or thinking problems, especially if you are an older adult.
• All other medicines, especially other anticholinergic medicines, or strong CYP3A4-inhibiting medicines such as ketoconazole.
• Whether you are pregnant, plan to become pregnant, or are breastfeeding.

How to take oxybutynin (as oxybutynin chloride/hydrochloride)

• Extended-release tablets must be swallowed whole with liquid -- do not chew, crush, or divide them. The tablet shell is not absorbed and may be visible in your stool afterward; this is expected and not a cause for concern.
• If you are using the Oxytrol transdermal patch, follow the product's own instructions for where and how often to apply it.
• Any change in dose, or a decision to stop oxybutynin, should be made together with your prescriber -- except when following the specific OTC product label instructions for the Oxytrol-for-Women patch in the United States.

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

If you miss a dose, contact your prescriber or pharmacist for guidance, or follow the specific instructions on the product label if you are using an OTC formulation such as the Oxytrol-for-Women patch.

Overdose

Seek urgent medical attention if you think too much oxybutynin has been taken, or if you notice severe confusion, hallucinations, a very fast heartbeat, difficulty breathing, or signs of severe anticholinergic effects such as extreme dry mouth, flushed hot skin, or an inability to urinate. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Serious warnings

Interactions

• Other anticholinergic medicines (such as certain antihistamines, some antidepressants, and other overactive bladder medicines): combining increases the total anticholinergic effect and side effects such as dry mouth, constipation, and confusion. (1) (2)
• Strong CYP3A4 inhibitor medicines (such as ketoconazole): can roughly double oxybutynin blood levels, potentially increasing side effects. (1)
• Medicines that increase gut movement (prokinetic medicines): oxybutynin can work against their intended effect. (2)
• Bisphosphonate medicines: caution advised, since anticholinergic medicines combined with bisphosphonates may worsen irritation of the oesophagus (gullet). (6)

Pregnancy, breastfeeding, kidney/liver function, age

Monitoring

Before starting

• Assessment for glaucoma, urinary retention risk, and gastrointestinal motility problems
• Review of other medicines for combined anticholinergic burden
• Baseline cognitive assessment in frail or older patients where relevant

During treatment

• Watching for early signs of angioedema, especially after starting or increasing the dose.
• Monitoring for anticholinergic side effects such as dry mouth, constipation, blurred vision, and confusion, particularly in older adults.
• Reassessing ongoing benefit versus side effects, since bladder symptoms and tolerability vary between individuals.

Storage

Store at room temperature, away from moisture and direct light, out of reach of children.

Frequently asked questions

References

1. OXYBUTYNIN CHLORIDE extended-release tablet -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information · United States · dated 2026-01-01 · accessed 2026-07-30 · source 1
2. Oxybutynin Hydrochloride 5mg Tablets -- Summary of Product Characteristics (SmPC)electronic medicines compendium (emc), United Kingdom -- Summary of Product Characteristics · United Kingdom · dated 2025-01-01 · accessed 2026-07-30 · source 2
3. Kentera (oxybutynin transdermal patch/gel) -- EPAR medicine overviewEuropean Medicines Agency (EMA) -- European Public Assessment Report (EPAR) · European Union · dated 2004-06-15 · accessed 2026-07-30 · source 3
4. DITROPAN XL (oxybutynin chloride) -- Product MonographHealth Canada -- Product Monograph (Ditropan XL, oxybutynin chloride) · Canada · dated 2015-01-01 · accessed 2026-07-30 · source 4
5. DITROPAN oxybutynin hydrochloride 5 mg tablet -- ARTG entry 48965Therapeutic Goods Administration (TGA), Australia -- Australian Register of Therapeutic Goods (ARTG) and PBS · Australia · dated 2026-07-01 · accessed 2026-07-30 · source 5
6. Oxybutynin (Alchemy) 5 mg tablets -- New Zealand Data SheetMedsafe (New Zealand Medicines and Medical Devices Safety Authority) -- New Zealand Data Sheet · New Zealand · dated 2025-06-17 · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient oxybutynin (as oxybutynin chloride/hydrochloride) names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries